Global Cord Blood Corporation Acquires Cellenkos, Inc.

Lonza AG Acquires PharmaCell BV

June 1, 2017

Biotechnology

Lonza AG has completed the acquisition of PharmaCell BV, a leading European contract manufacturer of cell and gene therapies with facilities in Maastricht and Sittard-Geleen. The deal expands Lonza's autologous cell-therapy manufacturing capabilities in Europe and integrates PharmaCell's GMP production capacity and experienced team into Lonza's global CDMO network.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

GBA Group Acquires KaLy-Cell SAS

September 5, 2022

Biotechnology

GBA Group has acquired French contract research organization KaLy-Cell SAS, marking the group's market entry into France and expanding its European pharmaceutical network. KaLy-Cell, founded in 2003 as a spin-off from the University of Bourgogne Franche-Comté and headquartered in Plobsheim, provides hepatocyte-based in vitro contract research and safety testing services for pharmaceuticals, agrochemicals and cosmetics.

Pfizer Acquires Global Blood Therapeutics for $5.4 Billion

August 8, 2022

Biotechnology

Pfizer Inc. has agreed to acquire Global Blood Therapeutics, Inc. for $68.50 per share in cash, valuing the transaction at approximately $5.4 billion including debt. The acquisition brings GBT's sickle cell disease portfolio (including Oxbryta) and pipeline to Pfizer to expand its rare hematology capabilities and accelerate access to therapies for underserved SCD patient communities.

Discovery Life Sciences Acquires AllCells

July 12, 2022

Biotechnology

Discovery Life Sciences has acquired AllCells to create an integrated, end-to-end provider of clinical-grade and RUO primary cell products and analytic services for the cell and gene therapy (CGT) continuum. The combined business — operating as AllCells, a Discovery Life Sciences Company and led by AllCells CEO Danny Zheng — aims to expand GMP-compliant starting materials, donor programs and multi‑omic characterization to accelerate CGT discovery through commercialization.

AnaBios Acquires Cell Systems

April 4, 2023

Biotechnology

AnaBios Corporation has acquired Cell Systems, a Kirkland, Washington supplier of human primary cells and cell culture media, to expand its human tissue and cell portfolio and accelerate translational drug discovery. Financing for the transaction was provided by AnaBios' existing investors, including Ampersand Capital Partners; financial terms were not disclosed.